Sexual wellness · Injectable
PT-141
Bremelanotide
Desire starts in the brain. So does this.
Bremelanotide, taken as needed. It works on the brain's melanocortin receptors rather than on blood flow. Evaluated by a licensed Apex MD provider and filled by a licensed U.S. pharmacy.
$249per month · injectable
SPENGA members: $50 off with code SPENGA50
- Physician prescribed
- Licensed U.S. pharmacy
- Ongoing medical support
- Arrives reconstituted
- Form
- Subcutaneous injection
- When
- As needed, 45+ minutes before
- Prescribed by
- Licensed Apex MD provider
- Also known as
- Bremelanotide
What it is
PT-141, in plain terms
PT-141 is bremelanotide, a synthetic seven-amino-acid peptide modelled on alpha-melanocyte-stimulating hormone, a hormone your body makes naturally.
Bremelanotide is the active ingredient in Vyleesi, which the FDA approved in 2019 for low sexual desire in premenopausal women. Compounded PT-141 is not itself FDA-approved, and use in men is off-label.
How it works
What it does in the body
Bremelanotide activates melanocortin receptors. Its effect on sexual response is thought to come from receptors in the hypothalamus, where it is believed to increase the signalling tied to desire and arousal.
That is a different route from medications such as sildenafil and tadalafil, which act on blood vessels. The approved product's label notes that the exact mechanism is not known.
The evidence
What the research shows, and what it doesn’t
Every finding is labelled by the kind of study it came from, with the source linked.
Human trial · phase 3
In two 24-week trials of 1,267 premenopausal women with low desire, bremelanotide improved desire scores and reduced distress more than placebo. The effect was statistically significant and modest in size.
Kingsberg et al., Obstetrics & Gynecology, 2019
Human trial
Across the phase 3 program, about 58% of women on bremelanotide were counted as responders, against about 35% on placebo.
Review of phase 3 data, 2022
Not yet studied
There are no large phase 3 trials in men and no FDA-approved use in men or in postmenopausal women. It is not indicated for enhancing sexual performance.
Vyleesi prescribing information, FDA
Published research describes what was observed in a study. It is not a promise of
what any product will do for you. Your provider will talk through what is realistic.
What to expect
On the protocol
01
How it's taken
A small injection just under the skin of the abdomen or thigh, taken as needed at least 45 minutes beforehand. No more than one dose in 24 hours. It arrives already reconstituted by the pharmacy, so there is no powder to mix and nothing to measure out.
02
What to expect
Effects typically begin within 30 to 60 minutes. Nausea is common with the first doses and tends to ease. Your provider may start you at a lower dose.
03
Blood pressure
Bremelanotide raises blood pressure slightly for several hours after a dose. That is why your provider asks about your heart and blood pressure history.
Safety
Know this before you start
Your provider reviews your full history. Tell them about every medication and
condition, including any history of cancer.
Reported side effects
- Nausea (about 4 in 10 people in clinical trials)
- Flushing (about 2 in 10)
- Headache and injection-site reactions
- A temporary rise in blood pressure
- Darkening of skin or gums, which may not fully reverse
Who should not use it
- Uncontrolled high blood pressure
- Known heart or cardiovascular disease
- Pregnancy or breastfeeding
- Anyone taking oral naltrexone
- A history of melanoma (tell your provider)
Tested athletes
Compete in a tested sport?
Bremelanotide is not currently named on the World Anti-Doping Agency Prohibited List. Tested athletes should confirm with Global DRO or their governing body before use.
FAQ
PT-141 questions, answered
Is PT-141 FDA-approved?
Bremelanotide is FDA-approved under the brand name Vyleesi for low sexual desire in premenopausal women. Compounded PT-141 is not FDA-approved, and use in men is off-label.
How is it different from Viagra or Cialis?
Those medications act on blood flow. PT-141 acts on melanocortin receptors in the brain that are involved in desire and arousal. Your provider can advise whether they can be used together.
How and when do I take it?
It is a small subcutaneous injection in the abdomen or thigh, taken as needed at least 45 minutes beforehand. Do not take more than one dose in 24 hours.
What are the most common side effects?
Nausea is the most common, affecting about 4 in 10 people in clinical trials, and it usually eases after the first couple of doses. Flushing, headache and injection-site reactions are also common.
Who should not use it?
Anyone with uncontrolled high blood pressure or known heart disease. It should not be used in pregnancy, and it should not be combined with oral naltrexone.
Does it work for men?
Small early studies showed it can produce erections in men. There are no large phase 3 trials in men and no FDA-approved male use, so results are less certain than for the approved use in women.
Keep looking
Other peptides for SPENGA members
Exclusive SPENGA member access
Start with PT-141
Answer a few questions. A licensed Apex MD provider decides whether it is right for you.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Prescription products require an online evaluation with a licensed medical professional, who will determine whether a prescription is appropriate. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality. Research cited on this site describes published studies and is not a claim about what any product will do for you. Individual results vary.
Sources
- Kingsberg et al., Obstetrics & Gynecology, 2019. https://pubmed.ncbi.nlm.nih.gov/31599840/
- Review of phase 3 data, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/
- Vyleesi prescribing information, FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf
- Rosen et al., Int J Impotence Research, 2004. https://www.nature.com/articles/3901200